Provided by Tiger Trade Technology Pte. Ltd.

MapLight Therapeutics, Inc.

13.00
-0.7850-5.69%
Post-market: 13.000.00000.00%19:30 EDT
Volume:340.17K
Turnover:4.50M
Market Cap:602.91M
PE:-2.57
High:14.14
Open:13.88
Low:12.80
Close:13.79
52wk High:40.43
52wk Low:9.10
Shares:46.38M
Float Shares:13.40M
Volume Ratio:0.58
T/O Rate:2.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.0580
EPS(LYR):-18.5643
ROE:-111.55%
ROA:-67.11%
PB:1.73
PE(LYR):-0.70

Loading ...

Sector Update: Healthcare

MT Newswires Live
·
Jul 22

MapLight Therapeutics Seen Having Upside in Schizophrenia Trial Readout, UBS Says

MT Newswires Live
·
Jul 22

UBS Adjusts MapLight Therapeutics Price Target to $52 From $48, Maintains Buy Rating

MT Newswires Live
·
Jul 21

MapLight Therapeutics price target raised to $52 from $48 at UBS

TIPRANKS
·
Jul 21

MapLight Therapeutics initiated with an Outperform at BMO Capital

TIPRANKS
·
Jul 21

Maplight Therapeutics Chief Discovery Officer Anatol Kreitzer Disposes of USD 1.34 Million in Common Shares

Reuters
·
Jul 20

Maplight Therapeutics CMO Erin Pennock Foff Sells USD 1.99 Million in Common Shares

Reuters
·
Jul 18

Analyst Maintains Buy on MapLight Therapeutics, Reaffirms $45 Price Target Ahead of Key Phase 2 ZEPHYR Readout

TIPRANKS
·
Jul 02

Maplight Therapeutics Director Martin Babler Files Initial Beneficial Ownership Statement

Reuters
·
Jun 26

Raymond James Initiates Coverage on MapLight Therapeutics With Strong Buy Rating

MT Newswires Live
·
Jun 25

Maplight Therapeutics Inc : Raymond James Initiates Coverage with Strong Buy Rating; Target Price $46

THOMSON REUTERS
·
Jun 25

Maplight Therapeutics Initiated at Strong Buy by Raymond James

Dow Jones
·
Jun 25

MapLight Shareholders Back Board Slate and Auditor

TIPRANKS
·
Jun 24

Maplight Therapeutics Shareholders Elect Three Directors at Annual Meeting

Reuters
·
Jun 24

Maplight Therapeutics Names Martin Babler, Troy Cox to Board of Directors

Reuters
·
Jun 24

Maplight Therapeutics Announces Changes to Board of Directors

THOMSON REUTERS
·
Jun 24

Craig-Hallum Sticks to Its Buy Rating for MapLight Therapeutics, Inc. (MPLT)

TIPRANKS
·
Jun 23

Overweight Rating Reaffirmed on ML004’s Irritability Efficacy and Safety Profile; $34 Price Target Maintained

TIPRANKS
·
Jun 23

MapLight Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
Jun 23

Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), MapLight Therapeutics, Inc. (MPLT)

TIPRANKS
·
Jun 23